Linked Life Data

11318115

Source:http://linkedlifedata.com/resource/pubmed/id/11318115

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-4-24
pubmed:abstractText
Although [131I]meta-iodobenzylguanidine (MIBG) is currently one of the best agents available for targeted radiotherapy, its use is confined to a few neural crest derived tumours which accumulate the radiopharmaceutical via the noradrenaline transporter (NAT). To determine whether this drug could be used for the treatment of non-NAT expressing tumours following genetic manipulation, we previously showed that plasmid mediated transfection of NAT into a non-NAT expressing glioblastoma cell line, UVW, endowed the host cells with the capacity to actively accumulate [131I]MIBG. We now present data defining the conditions required for complete sterilisation of NAT transfected cells cultured as multicellular spheroids and treated with [131I]MIBG.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1099-498X
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
165-72
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
pubmed:affiliation
Department of Radiation Oncology, Glasgow University, UK. gpma55@udcf.gla.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't